Summary & Overview
HCPCS J1805: Esmolol Hydrochloride Injection, 10 mg
HCPCS Level II code J1805 denotes a 10 mg injection of esmolol hydrochloride, a short-acting intravenous beta-blocker commonly used for rapid control of heart rate and blood pressure in acute, monitored settings. Nationally, accurate coding for parenteral cardiovascular agents like esmolol is important for clinical documentation, hospital revenue cycle management, and payer adjudication because dosing and administration context affect billing and utilization review.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for J1805, typical sites of service where the product is used, and the scope of payer coverage policies that influence reimbursement and claim processing. The publication also outlines common billing practices and benchmarking items—such as unit reporting, claim lines, and service-line implications—where available.
This summary provides clinicians, billing professionals, and policy analysts with a concise reference to the code’s clinical purpose and where it is commonly administered. Data not available in the input are noted as such in the detailed sections. The content does not provide clinical recommendations but supplies practical coding and policy context for operational and compliance needs.
Billing Code Overview
HCPCS Level II code J1805 represents an injection of esmolol hydrochloride, 10 mg. This billing code covers administration of a short-acting intravenous beta-blocker used for acute control of tachycardia and blood pressure in monitored medical settings.
Service Type: Intravenous drug administration
Typical Site of Service: Hospital inpatient, emergency department, or monitored outpatient infusion setting
Clinical & Coding Specifications
Clinical Context
A typical patient is a 62-year-old hospitalized individual admitted to a monitored acute care unit with new-onset supraventricular tachycardia or perioperative sinus tachycardia requiring short-acting beta blockade for rate control. The physician orders IV esmolol for rapid titratable infusion or bolus to reduce ventricular rate while assessing for reversible causes and planning definitive therapy. Nursing prepares the J1805 product (esmolol hydrochloride, 10 mg) per institutional medication administration protocols, confirms patient allergies, attaches continuous cardiac and blood pressure monitoring, and establishes intravenous access. The clinician administers an initial bolus or starts a weight‑based infusion, titrating to effect and hemodynamic tolerance, documenting dose, route, time, vital signs, and response. Typical sites of service include the emergency department, hospital inpatient unit, intensive care unit, post-anesthesia care unit, or procedural/surgical settings where short-acting beta blockade is required for acute rate control or intraoperative hemodynamic management.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
23 | Unusual Anesthesia | When general anesthesia was clinically appropriate but not administered due to circumstance — rarely used with medication billing except when tied to anesthesia reporting. |